Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Curr Med Res Opin. 2018 Dec 3;35(5):837–845. doi: 10.1080/03007995.2018.1541445

Figure 1.

Risk of incident VTE according to initial OAC therapy with dabigatran, rivaroxaban or apixaban versus warfarin* in patients with non-valvular AF, by patient characteristics, MarketScan databases, 2010 to September 30, 2015.

Figure 1.

*Matched on HDPS 1:1

AF: atrial fibrillation; OAC, oral anticoagulant; VTE: venous thromboembolism.